Journal article
Machine Learning Methods Enable Predictive Modeling of Antibody Feature: Function Relationships in RV144 Vaccinees
Ickwon Choi, Amy W Chung, Todd J Suscovich, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Robert J O'Connell, Donald Francis, Merlin L Robb, Nelson L Michael, Jerome H Kim, Galit Alter, Margaret E Ackerman, Chris Bailey-Kellogg
PLOS COMPUTATIONAL BIOLOGY | PUBLIC LIBRARY SCIENCE | Published : 2015
Abstract
The adaptive immune response to vaccination or infection can lead to the production of specific antibodies to neutralize the pathogen or recruit innate immune effector cells for help. The non-neutralizing role of antibodies in stimulating effector cell responses may have been a key mechanism of the protection observed in the RV144 HIV vaccine trial. In an extensive investigation of a rich set of data collected from RV144 vaccine recipients, we here employ machine learning methods to identify and model associations between antibody features (IgG subclass and antigen specificity) and effector function activities (antibody dependent cellular phagocytosis, cellular cytotoxicity, and cytokine rel..
View full abstractGrants
Awarded by Collaboration for AIDS Vaccine Discovery
Awarded by NSF
Awarded by National Health & Medical Research Center
Awarded by U.S. Army Medical Research and Material Command (USAMRMC)
Awarded by National Institutes of Allergy and Infectious Diseases
Awarded by Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Awarded by U.S. Department of Defense
Funding Acknowledgements
These studies were supported by the US Military HIV Research Program (MHRP), the Collaboration for AIDS Vaccine Discovery (OPP1032817: Leveraging Antibody Effector Function) to MEA, GA, and CBK, and NIH3R01Al080289-02S1 and 5R01Al080289-03 to GA. IC was supported by NSF grant IIS-0905206. AWC was supported by the American Australian Association (Amgen Fellowship) and National Health & Medical Research Center (NHMRC APP1036470). The work was also supported in part by an Interagency Agreement Y1-AI-2642-12 between the U.S. Army Medical Research and Material Command (USAMRMC) and the National Institutes of Allergy and Infectious Diseases and by a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.